WaveBreak
Joe Wilson is a Finance Director at WaveBreak, formerly known as Wren Therapeutics. Prior to this, Joe was the Head of Group Accounts at Petainer. Joe has a background in finance, with experience as a Senior Manager at KPMG and as an Audit Senior at Saffery Champness. Joe holds a Bachelor of Science degree in Mathematics and Economics from Durham University.
This person is not in any teams
This person is not in any offices
WaveBreak
WaveBreak is a biopharmaceutical company focused on transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS.